Posted On: 01/06/2015 12:04:39 PM
Post# of 30067
It'll be interesting to see what will be considered "good" now with adding early-stage into the mix.
http://content.stockpr.com/_news/amarantus/20...B_1854.pdf
Cheers
Quote:
Mr. Commissiong will review results of the full 140-subject LP-002 study assessing the predictive value of LymPro in patients with mild, moderate and severe AD. The results will include the dataset from the initial 72 patients showing that LymPro achieved highly statistically significant results in correctly distinguishing patients with moderate-to-severe AD from healthy controls and from the additional 68 patients in the study's extension to assess LymPro's predictive value in diagnosing early-stage AD .
http://content.stockpr.com/_news/amarantus/20...B_1854.pdf
Cheers
(0)
(0)
